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A number of studies have shown that foetal nutritional status significantly 
impacts an unborn child’s long-term health. The developmental origins of health 
and disease (DOHaD) hypothesis proposes that if a child is undernourished in 
the foetal period, the child will develop diabetes and hypertension in the future if 
adequate nutrition is given after birth. Moreover, hyperglycaemia (e.g. gestational 
diabetes mellitus [GDM]) experienced during foetal life can reportedly cause vari-
ous complications in children. As diabetes is increasing worldwide, so is GDM, and 
many studies have been conducted using GDM animal models and GDM cell lines. 
We examined the effects of streptozotocin-induced diabetes, particularly on the 
heart of offspring, in rat GDM animal models. We also analysed primary cardio-
myocyte cultures isolated from these GDM rats and found that insulin signalling 
was inhibited in GDM cells, as in the GDM animal models, by increased advanced 
glycation end products. Furthermore, the effect of eicosapentaenoic acid during 
pregnancy has been reported in GDM animal models and cells, and the findings 
indicated the importance of nutritional management for GDM during pregnancy.
Keywords: developmental origins of health and disease, fetus, high glucose, 
hyperglycaemia, advanced glycation end products, eicosapentaenoic acid
1. Introduction
Several studies have shown that foetal nutritional status has a significant impact 
on an unborn child’s long-term health. Barker et al. found that areas with high neo-
natal mortality between 1921 and 1925 had higher cardiovascular mortality between 
1969 and 1978 [1]. Barker et al. later reported that low birth weight correlated 
with glucose intolerance and cardiovascular disorders [2, 3]. Furthermore, they 
also proposed the Barker theory that “prenatal undernutrition increases the risk of 
lifestyle-related diseases in adulthood” [4]. Later, Gluckman and Hanson proposed 
the developmental origins of health and disease (DOHaD) hypothesis, which states 
that predisposition to lifestyle-related diseases is shaped by gene–environment 
interactions during fertilisation, embryonic development, foetal life, and infancy 
and that excessive nutrition after birth leads to the development of diabetes and 
hypertension (Figures 1 and 2) [5, 6].
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Figure 1. 
Foetal nutritional status has a major impact on postnatal health. It has been shown that even if the mother 
is undernourished during pregnancy, if the child is well nourished after birth, the child will develop diabetes 
and metabolic syndrome in the future. This has been defined as the developmental origin of health and 
disease (DOHaD) hypothesis. By contrast, GDM, an excessive nutrition (high glucose) environment during 
pregnancy, similarly increases the child’s risk of developing diabetes and metabolic syndrome in the future. 
Many studies have reported that nutritional status during pregnancy has a significant impact on the health 
of the child.
Figure 2. 
The diseases envisioned through the developmental origins of health and disease (DOHaD) hypothesis include 
learning disabilities, schizophrenia, high blood pressure, coronary heart disease, dyslipidaemia, decreased renal 
function, autism spectrum disorders, depression, and type 2 diabetes.
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This hypothesis is also supported by many epidemiological studies, which now 
clearly show that low birth weight increases the risk of developing a diverse array of dis-
eases, such as coronary artery disease, hypertension, stroke, diabetes, obesity, and met-
abolic syndrome. One example is the findings during the Dutch winter famine, wherein 
calorie intake had been temporarily lowered to 700 kcal/day for six months in 1944 due 
to the food embargo in the Netherlands during World War II. Children born during 
this period exhibited an increased risk of developing various diseases in adulthood, 
including glucose intolerance, lipid disorders, and ischemic heart disease. Moreover, 
during the starvation caused by China’s Great Leap Forward policy, those born during 
this period reportedly had an increased risk of type 2 diabetes and hypertension [7, 8]. 
Highly accurate and detailed birth record data such as birth weight, postnatal weight, 
and placental size were recorded at the University of Helsinki Hospital from 1934 to 
1944. Barker and his colleagues analysed the records and found that children with low 
birth weight were more likely to develop myocardial infarction, diabetes, and hyperten-
sion, as well as cognitive decline and depression in the future [9–12].
It is very difficult to prove a causal relationship between these foetal intrauterine 
environmental factors and their effects on the development of postnatal health and 
illness. However, in recent years, basic research using pregnant animal models as 
well as cell models are gradually clarifying the underlying molecular mechanism. 
In this chapter, we will introduce the findings on the effects of overnutrition, as rep-
resented by gestational diabetes mellitus (GDM), on animal offspring, rather than 
discuss findings from the perspective of undernutrition during the foetal period, 
which has already been extensively studied.
The structure of this paper is as follows: the introduction section describes the 
DOHaD theory and provides a description on the increasing number of diabetic 
patients worldwide; Section 2 provides an overview of gestational diabetes; Section 
3 describes the use of GDM animal models; Section 4 describes studies using 
hyperglycaemia cell models; and Section 5 describes the latest research on drug and 
diet therapy for GDM.
2. Gestational diabetes mellitus
The International Diabetes Federation (IDF) estimates that the global diabetes 
population continues to increase with 463 million people being pre-diabetic in 2019 
with a projected increase of up to 578 million by 2030. In addition, one in six women 
will develop abnormal glucose metabolism during pregnancy. The IDF has identified 
women with diabetes as a key challenge, with measures to improve the control of all 
types of diabetes being needed [13]. The prevalence of type 1 and type 2 diabetes 
in women of childbearing age is increasing, affecting about 1% of all pregnancies. 
Prevention is also important because of the increasing costs of diabetes care. Babies 
with extremely low or high birth weight are at high risk of diabetes [10]; therefore, 
nutritional management during pregnancy is important. Furthermore, inadequate 
glycaemic control in early pregnancy is associated with increased rates of con-
genital malformations, spontaneous abortions, stillbirths, and perinatal mortality 
[14–18]. It may also be associated with various pregnancy complications as well as 
neurodevelopmental disorders in the offspring. Similarly, long-term problems in the 
offspring due to insulin resistance may increase the risk of cardiovascular disease, 
hypertension, and diabetes mellitus (metabolic syndrome).
GDM is one of the most frequent complications of pregnancy, with an increas-
ing rate [19, 20]. The prevalence of GDM varies in direct proportion to the 
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prevalence of type 2 diabetes and is higher among Hispanic, African American, 
Native American, Asian or Pacific Islander, and South Mediterranean women [21, 
22]. It also varies by maternal age and diagnostic criteria [23, 24]. Since 2010, the 
international Association for the Study of Diabetes and Pregnancy (IADPSG) has 
tightened the criteria for the diagnosis of GDM, based on the 2008 Hyperglycemia 
and Adverse Pregnancy Outcomes (HAPO) study [25]. The reason for this was that 
the HAPO study reported a higher risk of macrosomia in newborn born to mothers 
with high blood glucose levels, even though GDM was not diagnosed using the pre-
vious criteria [26]. As a result, many GDM patients have been identified. The HAPO 
study was a large observational study of approximately 25,000 pregnant women 
with impaired glucose tolerance conducted in 15 centres across 9 countries; the 
correlation between blood glucose levels was examined at 24–32 weeks’ gestation 
with various pregnancy complications [27]. The endpoints of the diagnostic criteria 
for GDM were perinatal factors (heavy-for-dates infants, first caesarean section, 
neonatal hypoglycaemia, and hyperinsulinemia in the infant). The results showed 
that these perinatal complications were significantly associated with maternal 
blood glucose levels, even after adjusting for confounding factors such as maternal 
obesity. Furthermore, many epidemiological studies have shown that children born 
with GDM are associated with future development of noncommunicable diseases 
(NCDs) such as obesity and diabetes. Clausen et al. reported that the hyperglycae-
mic environment in utero and genetic background are associated with the future 
development of diabetes in children [28]. Sugihara et al. reported that infants born 
with macrosomia were also associated with childhood diabetes compared with low 
and normal birth weight [29].
Maternal undernutrition as well as GDM in an overnutrition environment are 
associated with the development of NCDs in future infants, indicating the impor-
tance of nutritional management during pregnancy (Figures 3 and 4) [29].
Figure 3. 
Similar to GDM, if the mother is hyperglycaemic, the foetus becomes exposed to hyperglycaemia. If 
hyperglycaemia persists, the foetus will develop insulin resistance and complications such as macrosomia and 
hypoglycaemia.
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3. Animal model for gestational diabetes mellitus
Diabetes in pregnancy increases the risk of various complications for both 
the mother and the child. However, the pathogenesis of GDM and its molecular 
mechanisms have not yet been fully elucidated. Animal and cell models are mainly 
used in basic research regarding GDM. GDM animal models play a major role in 
elucidating the pathogenesis and pathophysiology of diabetes, as well as elucidat-
ing the mechanisms of its complications. They also provide the theoretical basis 
for early detection and prevention of GDM and the subsequent clinical dosing and 
drug evaluation. Diabetes mellitus in humans is associated with complications such 
as peripheral neuropathy, nephropathy, and retinopathy in about 50% of cases, but 
there are few animal models that develop all complications; moreover, the animal 
models are selected according to the research purpose. The most widely used spe-
cies for diabetes animal models are the mouse and rat. The animal models for type 
1 diabetes range from animals that spontaneously develop autoimmune diabetes to 
those that chemically destroy pancreatic beta cells.
3.1 Spontaneous diabetic models
Spontaneous diabetic animals are not only produced by natural or selective 
breeding, but also by introducing genes from wild mice. The non-obese diabetic 
(NOD) mouse and bio breeding (BB) rat are the two most commonly used animals 
that spontaneously develop diseases similar to human type 1 diabetes. The NOD 
mouse was established by Makino et al. in the Shionogi Laboratory [30]. The BB rat 
was discovered in a commercial colony of Wistar-derived rats at the Bio-Breeding 
Laboratories in Ottawa, Canada [31].
The Goto-Kakizaki (GK) rat was established by Goto and Kakizaki as a  
non-obese, hypoinsulinemic model of type 2 diabetes [32]. GK rats are a diabetes 
model mainly due to their trait of non-obesity insulin deficiency established as 
in an inbred line by selective mating from Wistar rats using impaired glucose 
tolerance [33]. The Spontaneously Diabetic Torii (SDT) rats were established 
through inbreeding by selecting and mating Sprague–Dawley rats who developed 
Figure 4. 
The neonatal complications of GDM include foetal death, macrosomia, neonatal hypoglycaemia, 
hyperbilirubinemia, and neonatal respiratory distress syndrome; GDM also puts the mother at increased risk 
of developing type 2 diabetes (T2D) and cardiovascular disease in the future.
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diabetes [34]. The SDT rat is a novel model of type 2 diabetes that is non-obese, 
has hypoinsulinemic diabetes, and is characterised by the presence of diabetic 
retinopathy in individuals with prolonged hyperglycaemia [35]. Diabetes is 
prominent in males of this model, with diabetes occurring in almost 100% of 
males at 40 weeks. SDT rats develop proliferative retinopathy and are used as a 
model for human diabetic retinopathy [36].
3.2 Obese type 2 diabetes model animals
Spontaneous obesity-diabetes models (ob/ob mice, OLETF rat, KK and KKA 
mice, TSOD mice, SMXA5 mice, and Kuma mice) can be analysed for physiological, 
biochemical, and pathological changes during the onset and progression of type 2 
diabetes [37].
Ob/ob mice exhibit prominent overeating, are obese at 2 weeks of age, and reach 
a body weight of 40 g at 6 weeks and 60 g at 14 weeks. Later, in addition to overeat-
ing and obesity, the mice exhibit hyperglycaemia, hyperinsulinemia, and high blood 
glucagon levels. Insulin resistance is observed in the peripheral tissues and the liver.
Otsuka Long-Evans Tokushima Fatty (OLETF) rats were established as inbreed-
ing strains through the selective mating of diabetes-developing individuals found in 
Long-Evans rats. Binge eating obesity is exhibited immediately after weaning, and 
urinary sugar appears from 40 weeks after birth. Diabetes onset is prominent in 
males [38].
The KK mouse was established as an inbreeding strain from the experimental 
mouse produced in the Kasukabe region of the Saitama prefecture in Japan and was 
named KK mouse after Kasukabe [39]. KK mice are dominated by many diabetic 
genes, but their pathology is mild. Therefore, the KK-Ay mice were created, wherein 
the naturally mutated obesity gene, Ay, was introduced [40].
KK-Ay mice develop severe obesity and hyperglycaemia 7–8 weeks earlier than 
KK mice. The incidence of diabetes in males is approximately 100%. Nagoya-
Shibata-Yoshida (NSY) mice were established as inbreeding strains by selecting and 
mating ICR mice with impaired glucose tolerance. Impaired glucose tolerance and 
elevated blood glucose are exhibited after 8 weeks, and impaired glucose tolerance 
occurs in almost 100% of males at 48 weeks [41].
Tsumura Suzuki Obese Diabetes (TSOD) mice were established as inbreeding 
strains by selecting and mating ddY mice, which are highly reproductive non-
inbred mice, exhibiting urinary sugar and obesity. During the growth period of 4 
to 20 weeks of age, strong overeating is observed, and obesity is exhibited; more-
over, hyperglycaemia and abnormal lipid metabolism due to insulin resistance are 
likewise exhibited. The symptoms are strongly expressed in males [42].
SMXA5 mice are SMXA mice with recombinant inbreeding strains, as well as a 
high-fat diet-induced type 2 diabetes and fatty liver [43]. Impaired glucose toler-
ance and hyperinsulinemia frequently develop from 10 weeks of age. For Kuma 
mice, genome editing technology was used to obtain mice lacking glutamine, the 
104th amino acid of the insulin 2 protein, from the immunodeficiency model BRJ 
mice [44]. This mouse has elevated blood glucose levels after 4 weeks of age.
3.3 Animal model of chemistry-induced diabetes mellitus
Type 1 and type 2 diabetes models can be created by destroying islet of 
Langerhans cells in the pancreas through drug administration. The main advantages 
of this method are its relative ease in inducing a model of diabetes, not requiring the 
use of a specific strain, and the short development time. Most of these animals have 
type 1 diabetes, but depending on how the drugs are administered, models similar 
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to type 2 diabetes can also be created. The drugs used are streptozotocin (STZ) or 
alloxan (Alx). STZ is a nitrosourea derivative isolated from Streptomyces achromo-
genes [45]. Drug-induced diabetic rats can also be created from mature rats by intra-
venous administration of 30 mg/kg STZ or 40 mg/kg Alx. STZ administration to 
adult rats will produce a type 1 diabetic model, and administration to neonates will 
produce a type 2 diabetic-like model. Induction is usually done in early pregnancy, 
before the foetal pancreas has developed, to avoid foetal beta cell destruction by 
the chemicals being utilised. Alx can create a diabetes model by generating reactive 
oxygen species (ROS) in the beta cells of the pancreas and destroying these cells.
3.4 Surgically-induced models
Surgical models of diabetes were first created through canine pancreatectomy. 
In particular, GDM models were created through canine pancreatectomy at various 
stages of gestation [46]. The disadvantage of this model is that it lacks specificity, 
as both endocrine and exocrine tissues are removed, causing other symptoms not 
associated with diabetes mellitus. This is a model of GDM due to insulin deficiency, 
and not insulin resistance [46]. As mentioned above, there are spontaneous animal 
models and transgenic animal models of diabetes, but most of them often show 
remarkable symptoms in males. Since the pregnancy and childbirth of hypergly-
caemic mothers are often difficult, the effects of the intrauterine hyperglycaemic 
environment on children cannot be observed. Thus, we used chemical virulence 
factors to cause specific damage to the beta cells in the pregnant animal’s pancreas, 
inducing complications similar to GDM. Therefore, we obtained the offspring from 
the GDM animal model by mating normal Wistar rats and then administering STZ 
to the tail vein, rather than using diabetic model rats.
4. Intrauterine hyperglycaemia-mimicking cell model
In the case of GDM, foetation is exposed to maternal hyperglycaemia through the 
placenta during the foetal period. The DOHaD study described in the Introduction 
mainly focused on the effects of inadequate nutrition during the foetal period (intra-
uterine undernutrition environment) on the future development of disease in the 
offspring [4–6]. When the womb provides over-nutrition, the offspring will exhibit 
numerous complications, as previously described. Recently, studies have been 
conducted that mimic the hyperglycaemic environment by changing the glucose 
concentration in the medium using primary cultured cells and cell lines. Nerve cells 
and skeletal muscle cells, among others, in which cells differentiate and their fate 
is determined during the foetal period, are important. Although it is possible to use 
primary cultured cells isolated from foetal organs for these studies, the experiments 
may be limited because the differentiated cells do not proliferate. Therefore, by using 
a cell line, the cells can be handled more easily than primary cells.
Myocardial blasts established from rats are often used as heart model cells [47]. 
The exposure of H9C2 cells to Dulbecco’s modified Eagle’s medium containing 
50 mM high glucose was compared with a medium containing 5.5 mM glucose (the 
normoglycemic level), and the H9C2 cells reportedly exhibited apoptosis in the 
high glucose medium [48]. Another study with H9C2 cells showed that simvastatin 
has an autophagy-mediated cardioprotective effect; this study used a cell model 
wherein exposure to 200 mM high glucose induced cardiomyocyte apoptosis [49]. 
Studies using these myocardial blast cell lines suggest that high glucose in an intra-
uterine hyperglycaemic environment has a profound effect on foetal myocardial 
blast signalling and proliferation.
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PC12 cells, which are pheochromocytoma cells derived from the adrenal gland 
of Rattus norvegicus, are often used in the study of nerve cells [50]. PC12 cells can 
be differentiated using the nerve growth factor (NGF) to investigate the effects on 
neurons [51]. Furthermore, high glucose has been shown to cause oxidative stress-
induced apoptosis in dopaminergic neurons. Studies with PC-12 cells revealed a cor-
relation between hyperglycaemia and neurodegeneration using a PC-12 cell model 
exposed in a high glucose medium. Resveratrol, a polyphenol contained in red wine, 
suppresses nerve cell death due to apoptosis induced by a high glucose environment 
[52]. Similar studies have been conducted on PC12 cells, indicating that resveratrol 
or alpha-lipoic acid protected PC12 cells from HG-induced oxidative stress and 
apoptosis through activation of the PI3K/Akt/FoxO3a signalling pathway [53, 54]. 
These results suggest that the intrauterine hyperglycaemic environment during 
pregnancy may lead to inflammation and apoptosis of foetal neurons due to long-
term exposure to foetal hyperglycaemia.
Next, we present a study of the effects of high glucose on cells in a skeletal 
muscle cell model of GDM. Skeletal muscle is an essential organ for energy metabo-
lism. During foetal development, myoblasts differentiate into skeletal muscle dur-
ing development. Several cell-level studies on how the hyperglycaemic environment 
affects the differentiation of myoblasts into skeletal muscle are being conducted. 
In a cell model using mouse myoblasts C2C12, high glucose exposure of 25 mM 
was shown to accelerate myogenesis by rearranging SUMO enzyme transcripts and 
SUMO proteins [55]. However, other experiments with C2C12 have shown that 
even higher glucose concentrations of 60 mM inhibit the expression of the MyoD 
and myogenin genes, as well as the Akt signal, suppressing skeletal muscle dif-
ferentiation [56]. High glucose was also shown to interfere with the proliferation of 
muscle-specific stem cells and satellite cells under adherent culture conditions [57]. 
Therefore, it is suggested that hyperglycaemia may promote sarcopenia. Glucose is 
also suggested to be a factor that determines the cell fate of skeletal muscle-specific 
stem cells. Recently, we found that high glucose (25 mM) in the medium increases 
the expression of skeletal muscle differentiation marker genes such as MyoD and 
myogenin compared to normal glucose levels (5 mM), resulting in ROS develop-
ment and Akt signalling. The differentiation of myoblasts into skeletal muscle was 
reportedly promoted by high glucose [55]. The appearance of unusually large babies 
with gestational diabetes complications may be due in part to excessive muscle 
differentiation.
5. Our study on intrauterine hyperglycaemia
While there have been many studies using animal and cellular models of GDM, 
few studies have analysed the effects of GDM on the pups born from it. We have 
previously studied the effects of STZ-induced GDM on the heart of pups using a rat 
model of GDM. In this section, we describe (1) the effects of a high-fat diet during 
pregnancy on the hearts of GDM rat pups, (2) the effects of fish oil intake during 
pregnancy on the hearts of GDM rat pups, and (3) the effects of eicosapentaenoic 
acid (EPA) intake during pregnancy on primary cardiomyocyte cultures isolated 
from GDM rat pups.
5.1 Effect of a high-fat diet on stillbirth rate during pregnancy in GDM model 
rats
GDM model rats were created by administering STZ (50 mg/kg) into the tail vein 
of Wistar rats on the second day of pregnancy. To investigate the effect of a high-fat 
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diet during pregnancy on the pups, GDM rats were fed a high-fat lard diet (56.7% 
fat) containing saturated fatty acids and a control diet (7% fat). The stillbirth rate of 
GDM rats on the high-fat lard diet was much higher than that of GDM on the control 
diet [58]. Palmitic acid, a saturated fatty acid, has been reported to cause inflamma-
tion and cardiac dysfunction in animal and cellular level experiments [59]. In addition 
to exposure to hyperglycaemia in utero, the consumption of a high-fat lard diet high 
in saturated fatty acids may have impaired cardiac function in the pups.
5.2 Effect of fish oil intake on the heart of rat pups in the GDM model
In this study, we examined the effects of fish oil (which is rich in ω3 unsaturated 
fatty acids) on pups, based on reports that fish oil has a positive effect on cardiovascular 
diseases [60, 61]. GDM rats were fed a high-fat fish oil diet (14% fish oil + 7% lard), a 
high-fat lard diet rich in saturated fatty acids (21% lard), and a normal diet (7% lard), 
and the heart signals of the pups were then analysed. The pups of GDM rats fed the 
lard diet had higher stillbirth rates and triglyceride levels, but these were improved in 
the pups fed the fish oil diet [62]. An examination of Akt-related signalling revealed 
that pups born to GDM rats fed a lard diet had reduced levels of Akt phosphorylation, 
which is important for sugar uptake. Interestingly, however, these signalling abnormali-
ties were ameliorated in the hearts of pups born to GDM rats fed a fish oil diet during 
pregnancy.
5.3 Effect of EPA intake on primary cardiomyocytes of rat pups in the GDM rat 
model
Our results indicate that intrauterine hyperglycaemia induces abnormal 
insulin signalling in the foetal heart. Why does abnormal heart signalling occur 
Figure 5. 
Prolonged hyperglycaemia leads to excessive glycation of proteins and accumulation of advanced glycation end 
products (AGEs), which induce inflammation and inhibition of Akt-related signalling, resulting in insulin 
resistance. In addition, AGEs induced by hyperglycaemia lead to the production of ROS, which in turn induce 
apoptosis by increasing BAX and degrading caspase.
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in the pups? What components of fish oil can be ingested by pregnant mothers 
to improve the condition? Fish oil is a rich source of the n-3 unsaturated fatty 
acids EPA and DHA. EPA was chosen as a candidate because it has cardiovascular 
protective properties, and DHA is biosynthesised by the body from EPA. GDM 
rats were orally administered EPA through gavage during pregnancy. Primary 
cardiomyocyte cultures isolated from the hearts of the pups were examined for 
effects on the insulin signalling system [63]. We found that the inhibition of 
insulin signalling in primary cardiomyocyte cultures from GDM rats inhibited the 
translocation of GLUT4 to the plasma membrane. Why do these signalling abnor-
malities occur? In cultured primary cardiomyocytes from GDM rats, ROS was 
generated and an increase in excessive protein advanced glycation end products 
(AGEs) was observed. This AGEsation has been highlighted as a cause of ageing 
and disease. The accumulation of AGEsed proteins also increases the expression 
of the receptor of AGEs (RAGE), which triggers AGEs-RAGE signalling. This 
AGEs-RAGE signalling was found to increase various pro-inflammatory cytokine 
genes (IL-6, TNFα, and NF-κB) through JNK phosphorylation (Figure 5). These 
results indicate that exposure to hyperglycaemia in the foetus of GDM rats leads 
to increased AGEs oxidation and chronic inflammation. However, GDM rats fed 
EPA (an ω3 unsaturated fatty acid) during pregnancy were shown to ameliorate 
the abnormalities in the pups.
6. Diet and drug therapy for GDM
What other drugs are effective against GDM besides insulin? The effect 
of using metformin and insulin on GDM has already been reported [64]. 
Metformin is associated with a decreased incidence of GDM [65]. The weight 
of  metformin-treated neonates is lower than that of insulin-treated neonates. 
In addition, metformin-treated infants had lower rates of weight gain and 
malformations during pregnancy than insulin-treated infants. In contrast, 
 metformin-treated infants had greater weight gain in the neonatal period, 
with no difference in weight between those administered with insulin and 
metformin. This suggests that weight gain during this period may be linked 
to cardiovascular disease and indicates the need for additional research. We 
have previously investigated dietary treatment in GDM rats. EPA, an n-3 
unsaturated fatty acid, was administered to GDM rats from day 1 to day 22 
of gestation and the effect on new-born rats was investigated. In the heart 
of  puppies born to GDM rats, excessive AGE formation of cardiac proteins 
impaired signal transduction, but feeding EPA to GDM rats inhibited AGE 
formation and improved signal transduction. Since AGE is the cause of vari-
ous diseases [65], several drugs have been developed to inhibit AGEs. The 
accumulation of AGEs has been reported to induce inflammation and damage 
vascular endothelial cells, smooth muscle cells, and fibroblasts [66]. In addi-
tion to diabetes mellitus, other diseases wherein AGEs are involved include 
neurodegenerative diseases, cardiovascular diseases, chronic renal failure, and 
autoimmune diseases [67]. AGE formation inhibitors, AGE destroyers, AGEs-
RAGE inhibitors, and signal transduction inhibitors have been previously 
reported [68–72]. For example, studies on AGE formation inhibitors found that 
some amino acids in the plasma inhibit glycation by competitively inhibiting 
the molecular binding of glucose to proteins [73]. Furthermore, AGE-RAGE 
 inhibitors have been shown through animal studies to be protective against 
diabetic  nephropathy when DPP4 is deficient or when DPP4 inhibitors are 
added [74].
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7. Conclusion
Undernutrition or overnutrition during pregnancy has profound effects not only 
on the mother but also on the child. Children with GDM are focused on neonatal 
complications, but in the future, they may suffer from lifestyle-related and mental 
illnesses. Elucidation of these molecular mechanisms is becoming clear using 
animal models and cell models. Thus, GDM has a major impact on the mother as 
well as on the child and should be treated rigorously with medication and diet. 
Insulin is the main drug therapy for controlling blood glucose, but in addition to 
insulin, insulin resistance improving drugs such as metformin have been tried, but 
the safety is still unknown. Therefore, dietary management is essential for GDM in 
addition to safe medication.
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